Cornes, Paul http://orcid.org/0000-0002-7835-7873
Gascon, Pere
Vulto, Arnold G. http://orcid.org/0000-0002-8439-2800
Aapro, Matti
Article History
First Online: 30 March 2020
Compliance with Ethical Standards
:
: This work was supported by Accord Healthcare, which provided funding to Strategen Limited for editorial services in relation to the production of this article. Accord had no input into the editorial content or the final article. The statements, findings, conclusions, views and opinions contained and expressed herein are not necessarily those of Accord or any of its affiliated or subsidiary entities. Accord provided funding for Open Access.
: The authors received no financial support for the development of this article. Paul Cornes declares honorarium or support for attending meetings from Accord Healthcare, Amgen, Astro Pharma, European Association for Hospital Pharmacists, European Commission, Medicines for Europe/European Generics Association, Medscape, Mylan, Napp, Pfizer/Hospira, Sandoz and Teva. Pere Gascon declares honorarium and support for attending meetings/lecturing from Accord Healthcare, Amgen, Sandoz and Pfizer/Hospira. Arnold G. Vulto has conducted biosimilar research sponsored by Hospira (now Pfizer) and declares honorarium or support for consulting, advisory work and speaking engagements from AbbVie, Accord Healthcare, Amgen, Biogen, Fresenius-Kabi, Medicines for Europe, Pfizer/Hospira, Mundipharma, Roche and Sandoz. Matti Aapro declares received honoraria and/or consultant support from Accord Healthcare, Amgen, Bayer, BMS, Celgene, Cephalon, Chugai, Clinigen, Eisai, GenomicHealth, GSK, Helsinn, Hospira, Ipsen, J&J, Kyowa, Merck, Novartis, OrthoBiotech, Pfizer, PierreFabre, Roche, Sandoz, Sanofi, Tesaro, Taiho, Teva and Vifor.